TrialJournal of the National Cancer Institute1998

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

S A Rosenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.